Venture_Socks_RZ_RGB_300dpi(2)_edited.pn
icon-prizes.png

WINNERS

orange arrows.png

Haya Therapeutics SA

2019

Health & Nutrition

2000_W1_Carbofix.png
Sensirion_edited.jpg

HAYA Therapeutics is developing a proprietary anti-fibrotic therapy for myocardial fibrosis and heart failure by targeting a master regulator of fibrosis in the heart, Wisper. Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. HAYA will also implement a target discovery engine to develop a pipeline of lncRNA anti-fibrotic targets in multiple tissues/indications.